Sacred Plants and Mental Health in Latin America
DOI:
https://doi.org/10.5281/zenodo.7235793Abstract
Sacred plants have a number of phenomena that revolve around their ritual and medicinal use, as well as being seen as carrying a bond with the sphere of the sacred. México is the country that has the greatest diversity of sacred plants in the Americas because its indigenous groups have a magical-religious relationship with them. In the beginning of the study of sacred plants, psilocybin, mescaline and ergotamine began to be classified as classical psychedelics, this categorization was of great help to psychiatry and neuroscience in the 1950s and 1960s.
Literaturhinweise
➔ Anderson T, Petrankerz R, Rosenbaum D, Weissman C, Williams A, Huis, K, Hapkes E, (2018). Microdosing psychedelics:personality, mental health and creativity, differences in microdosers. Journal of Psychopharmacology.
➔ Barone W. Beck j & Mitsunaga-Whitten. (2019). Perceived benefits of MDMA – Assiste psychotherapy beyond symptom reduction: qualittaive follow -uo study of a clinical trial for individual with treatment- resistan PTSD. Journal of Psychoactive Drugs. 2019 March 8. Doi:10.1080/02791072.2019.1580805
➔ Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627. doi:10.1016/S2215-0366(16)30065-7
➔ De Gregorio, Enns, Nuñez, Posa & Gobbi. (2018). D-Lysergic acid diethylamide, psilocybin and other classic hallucinogens: Mechanism of action and potential therapeutic applications in modo disorders. Progress in Brain Research. Elsevier
➔ Eliade Mircea (1998). Sagrado y profano. Barcelona, Paidos.
➔ European Monitoring Centre for Drugs and Drug Addiction. (2016). European Drug Report 2016: Trends and Developments. Publications Office of the European Union, Luxembourgp
➔ Johnson, MW, Hendricks,PS, Barret FS, Griffiths,RR. (2018). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics Journal, December 4, 2018.
➔ Samorini,G. (2001). Los alucinógenos en el mito. La Liebre de Marzo. Barcelona
➔ Schultes R.E & Hofmann A. (1983). Plantas de los dioses: Orígenes del uso de los alucinogenos. Fonde de Cultura Económica. México ➔ Organización Mundial de la Salud. (2004). Invertir en salud mental. Ginebra. Suiza.
➔ United Nations (2015) Transforming our world: The 2030 agenda of sustainable development. Geneve. Switzerland
➔ World Health Organization (2013). Investing in mental health: Evidence for action. Geneve,Switzerland.
Downloads
Veröffentlicht
Zitationsvorschlag
Ausgabe
Rubrik
Kategorien
URN
Lizenz
Copyright (c) 2019 M.Sc. Oscar Espin
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung - Nicht-kommerziell 4.0 International.
All authors who publish their work in this journal give their patrimonial rights in favor of the JMSHRS on a non-exclusive basis. This means that authors may enter into other independent and contractual agreements to disseminate their text published in this journal. Such as, for example, including it in an institutional, thematic or other repository, publishing it in a book, or other digital or physical media, as long as they explicitly indicate that the work was first published in this journal.
The responsibility for the content of each published work corresponds exclusively to the authors themselves, excluding the editors from any legal responsibility.
The contents of the journal will be disseminated under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). All issues are open access (OA) from the moment of publication.